Alnylam Pharmaceuticals, Inc.

in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call we require immediate assistance, please press 4-0 for the operator. I would now like to turn a conference call over to the company. Please go ahead.

Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Breenstreet, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Pushkal Garg, Chief Medical Officer, and Jeff Poulton, Chief Financial Officer. For those of you participating in a conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.l911.com slash events. During today's call, as outlined in slide two, Yvonne will offer introductory remarks and provide some general context. FOBA will provide an update on our global commercial progress, Chris will review pipeline updates and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions. I would like to remind you that this call will contain remarks concerning LNILAM's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Security Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file of the SEC. In addition, any forward-looking statements represent our views only of the date of this recording and should not be relied upon representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Yvonne. Yvonne?

Thanks, Christine, and thank you everyone for joining the call today. 2024 was a fantastic year for Alnylam, with strong research, program development, and commercial execution, and significant progress across the business. This includes the highly positive results in the HDSG Phase III study, leading to submission of global regulatory filings for vitreous saran and ATTR cardiomyopathy. We also continue to advance and expand our robust and high-value pipeline of clinical programs. And we continue to demonstrate strong commercial and financial performance, achieving combined and net product revenues of over $1.6 billion at the upper end of our revised guidance range. And we delivered $95 million in non-GAAP operating income for the full year, marking a significant milestone for the company. Furthermore, we maintained our award-winning culture, which has been a critical enabler of our success. As we look to the year ahead, 2025 has the potential to be a landmark year for our Nilem. We believe that there are three core elements of our business that will drive sustainable growth and value creation, not just in 2025, but for years to come, and will take our Nilem into its next exciting chapter. The first is TTR leadership, where Vutrisiran, if approved, has the potential to become a new standard of care in ATTR cardiomyopathy and establish a flagship franchise for our company with the advancement of our next generation TTR asset, Nucrisiran, following along. Next is growth through innovation, including a pipeline with numerous multi-billion dollar opportunities and an R&D engine set up to deliver sustainable innovation and value creation. The third pillar is strong financial performance, where we project that our robust commercial delivery and disciplined approach to capital allocation will enable us to sustain profitability going forward. All of this is underpinned by a best-in-class team and our award-winning culture. All of this represents tremendous progress against our nylon pizza fifth by 25 goals launched back in 2021. We're now on the cusp of turning these goals into reality and believe that in doing so, we're on track to become a top tier biotech. Furthermore, the progress we make in 2025 will set us up for the second half of the decade and our next era of significant growth. We are entering a new and exciting chapter in our Nilem's history and truly believe the best is yet to come. With that, Let me now turn the call over to Tolga for a review of our commercial performance. Tolga?